Cardlytics, Inc. CDLX

Investing.com -- SimilarWeb Ltd (NYSE:SMWB) shares fell over 7% Thursday following the company's announcement that Michael Akkerman will become Chief Executive Officer, effective November 2, 2026.

Moby summary of Cardlytics, Inc.'s Q2 2026 earnings call

ATLANTA, August 05, 2026--Cardlytics, Inc. (NASDAQ: CDLX), a purchase intelligence platform, today announced financial results for the second quarter ended June 30, 2026.

ATLANTA, July 31, 2026--Cardlytics, Inc. (NASDAQ: CDLX) today announced that on July 29, 2026, the Compensation Committee of Cardlytics’ Board of Directors granted an aggregate of 10,320 restricted stock units of Cardlytics to 10 newly hired employees. The restricted stock units were granted as material inducements to employment with Cardlytics in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Cardlytics, Inc. 2022 Inducement Plan (the "2022 Inducement Plan").

ATLANTA, July 29, 2026--Cardlytics Inc. (NASDAQ: CDLX) today announced the appointment of Chris Cheng as Chief Legal Officer, effective August 3, 2026. Cheng will serve on the Leadership Team and oversee Cardlytics Legal and Compliance organization.

ATLANTA, July 21, 2026--Cardlytics, Inc. (NASDAQ: CDLX) today announced that its financial results for the second quarter ending June 30, 2026 will be released on August 5, 2026, after market close.

The draft update would require investment companies to take contractual sale restrictions into account when valuing an equity security at fair value.

We recently compiled a list of the 10 Best Penny Stocks Under $1 According to Hedge Funds. Cardlytics, Inc. (NASDAQ:CDLX) is among the best penny stocks. TheFly reported on May 8 that Lake Street reduced its price target on CDLX to $1.25 from $1.50 while reiterating a Hold rating, citing a reset in expectations following […]

As you might know, Cardlytics, Inc. ( NASDAQ:CDLX ) just kicked off its latest quarterly results with some very strong...

Moby summary of Cardlytics, Inc.'s Q1 2026 earnings call

Cardlytics is back in focus after analysts reset price targets closer to the US$1 to US$1.25 range, with a fair value estimate holding near US$1.04. These changes sit alongside commentary that Q4 results, Q1 guidance, the BofA exit, and the Bridg divestiture now leave the "bar appropriately level set," with some calling the shares firmly in "show me" territory. As you read on, you will see how to track this evolving analyst narrative and what it can mean for your own view on the stock. Stay...

Cardlytics is back in focus after its latest fair value estimate was trimmed from US$1.29 to US$1.04, pointing to a lower price target in the updated analyst narrative. Much of this reset is being linked directly to Q4 results, Q1 guidance, and the revenue implications of the BofA exit and Bridg divestiture, which have pushed analysts to mark expectations closer to current realities. Reading on, you will see how bullish and bearish voices are framing these changes and how you can track the...